Cross-talk between Myc and p53 in B-cell lymphomas
- Author:
Yu LI
1
;
Yu TIAN-TIAN
;
Ken H. YOUNG
Author Information
1. Department of Hematology,The Second Affiliated Hospital to Nanchang University,Nanchang,Jiangxi 330006,China;Hematopathology Division and Pathology Department,Duke University School of Medicine,Durham,NC 27710,USA
- Publication Type:Journal Article
- Keywords:
B-cell lymphoma;
p53;
Myc;
Molecular mechanisms;
Targeted therapy
- From:
Chronic Diseases and Translational Medicine
2019;5(3):139-154
- CountryChina
- Language:English
-
Abstract:
Myc and p53 proteins are closely associated with many physiological cellular functions, including immune response and lymphocyte survival, and are expressed in the lymphoid organs, which are sites for the development and activation of B-cell malignancies. Genetic alterations and other mechanisms resulting in constitutive activation, rearrangement, or mutation of MYC and TP53 contribute to the development of lymphomas, progression and therapy resistance by gene dysregulation, activation of downstream anti-apoptotic pathways, and unfavorable microenvironment interactions. The cross-talk between the Myc and p53 proteins contributes to the inferior prognosis in many types of B-cell lymphomas. In this review, we present the physiological roles of Myc and p53 proteins, and recent advances in understanding the pathological roles of Myc, p53, and their cross-talk in lymphoid neoplasms. In addition, we highlight clinical trials of novel agents that directly or indirectly inhibit Myc and/or p53 protein functions and their signaling pathways. Although, to date, these trials have failed to overcome drug resistance, the new results have highlighted the clinical efficiency of targeting diverse mechanisms of action with the goal of optimizing novel therapeutic op-portunities to eradicate lymphoma cells.
